» Articles » PMID: 33818906

Controlled Aggregation Enhances Immunomodulatory Potential of Mesenchymal Stromal Cell Aggregates

Overview
Date 2021 Apr 5
PMID 33818906
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Human mesenchymal stromal cells (MSCs) are promising candidates for cell therapy due to their ease of isolation and expansion and their ability to secrete antiapoptotic, pro-angiogenic, and immunomodulatory factors. Three-dimensional (3D) aggregation "self-activates" MSCs to augment their pro-angiogenic and immunomodulatory potential, but the microenvironmental features and culture parameters that promote optimal MSC immunomodulatory function in 3D aggregates are poorly understood. Here, we generated MSC aggregates via three distinct methods and compared them with regard to their (a) aggregate structure and (b) immunomodulatory phenotype under resting conditions and in response to inflammatory stimulus. Methods associated with fast aggregation kinetics formed aggregates with higher cell packing density and reduced extracellular matrix (ECM) synthesis compared to those with slow aggregation kinetics. While all three methods of 3D aggregation enhanced MSC expression of immunomodulatory factors compared to two-dimensional culture, different aggregation methods modulated cells' temporal expression of these factors. A Design of Experiments approach, in which aggregate size and aggregation kinetics were systematically covaried, identified a significant effect of both parameters on MSCs' ability to regulate immune cells. Compared to small aggregates formed with fast kinetics, large aggregates with slow assembly kinetics were more effective at T-cell suppression and macrophage polarization toward anti-inflammatory phenotypes. Thus, culture parameters including aggregation method, kinetics, and aggregate size influence both the structural properties of aggregates and their paracrine immunomodulatory function. These findings underscore the utility of engineering strategies to control properties of 3D MSC aggregates, which may identify new avenues for optimizing the immunomodulatory function of MSC-based cell therapies.

Citing Articles

Mesenchymal stromal cell derived extracellular vesicles as a therapeutic tool: immune regulation, MSC priming, and applications to SLE.

Wong C, Stoilova I, Gazeau F, Herbeuval J, Fourniols T Front Immunol. 2024; 15:1355845.

PMID: 38390327 PMC: 10881725. DOI: 10.3389/fimmu.2024.1355845.


Spheroid size influences cellular senescence and angiogenic potential of mesenchymal stromal cell-derived soluble factors and extracellular vesicles.

Rovere M, Reverberi D, Arnaldi P, Palama M, Gentili C Front Bioeng Biotechnol. 2024; 11:1297644.

PMID: 38162179 PMC: 10756914. DOI: 10.3389/fbioe.2023.1297644.


Whole transcriptomic analysis of mesenchymal stem cells cultured in Nichoid micro-scaffolds.

Testa C, Oliveto S, Jacchetti E, Donnaloja F, Martinelli C, Pinoli P Front Bioeng Biotechnol. 2023; 10:945474.

PMID: 36686258 PMC: 9852851. DOI: 10.3389/fbioe.2022.945474.


Perinatal Stem Cell Therapy to Treat Type 1 Diabetes Mellitus: A Never-Say-Die Story of Differentiation and Immunomodulation.

Paris F, Pizzuti V, Marrazzo P, Pession A, Alviano F, Bonsi L Int J Mol Sci. 2022; 23(23).

PMID: 36498923 PMC: 9738084. DOI: 10.3390/ijms232314597.


Co-aggregation of MSC/chondrocyte in a dynamic 3D culture elevates the therapeutic effect of secreted extracellular vesicles on osteoarthritis in a rat model.

Esmaeili A, Hosseini S, Kamali A, Hosseinzadeh M, Shekari F, Baghaban Eslaminejad M Sci Rep. 2022; 12(1):19827.

PMID: 36400827 PMC: 9674636. DOI: 10.1038/s41598-022-22592-4.


References
1.
Wheeler K, Jena M, Pradhan B, Nayak N, Das S, Hsu C . VEGF may contribute to macrophage recruitment and M2 polarization in the decidua. PLoS One. 2018; 13(1):e0191040. PMC: 5764356. DOI: 10.1371/journal.pone.0191040. View

2.
Ylostalo J, Bartosh T, Tiblow A, Prockop D . Unique characteristics of human mesenchymal stromal/progenitor cells pre-activated in 3-dimensional cultures under different conditions. Cytotherapy. 2014; 16(11):1486-1500. PMC: 4190045. DOI: 10.1016/j.jcyt.2014.07.010. View

3.
Raghavan S, Mehta P, Horst E, Ward M, Rowley K, Mehta G . Comparative analysis of tumor spheroid generation techniques for differential in vitro drug toxicity. Oncotarget. 2016; 7(13):16948-61. PMC: 4941362. DOI: 10.18632/oncotarget.7659. View

4.
Zimmermann J, Hettiaratchi M, McDevitt T . Enhanced Immunosuppression of T Cells by Sustained Presentation of Bioactive Interferon-γ Within Three-Dimensional Mesenchymal Stem Cell Constructs. Stem Cells Transl Med. 2017; 6(1):223-237. PMC: 5442746. DOI: 10.5966/sctm.2016-0044. View

5.
Lawrence T . The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2010; 1(6):a001651. PMC: 2882124. DOI: 10.1101/cshperspect.a001651. View